Global Medical Device Venture Financing Deals Total $3.84 Billion in Q4 2020

The COVID-19 pandemic took a big bite out of medtech venture financing in the final quarter of 2020.

Total deal value was $3.84 billion, a 17.7 percent drop compared to the third quarter and a 2.8 percent slide compared with the $4 billion total recorded in Q4 2019, according to GlobalData. 

North America was the top region for financing, with total announced transactions worth $2.31 billion between Oct. 1 and Dec. 31, 2020. Deal value was highest in the United States.   

In terms of volumes, North America emerged as the top region for medical devices industry venture financing deals globally, followed by Asia-Pacific and then Europe.
 
The top country in terms of venture financing deals activity in Q4 2020 was the United States with 123 deals, followed by China with 51 and Switzerland with 11.
 
In 2020, as of the end of Q4 2020, medical devices venture financing deals worth $16.43 billion were announced globally, marking an increase of 49.6 percent year on year.
 
The top five medical devices industry venture financing deals accounted for 19 percent of the overall value during the fourth quarter of 2020.
 
The combined value of the top five medical devices venture financing deals stood at $729 million, against the overall value of $3.84 billion recorded for the quarter.
 
The top five medical devices industry deals of Q4 2020 tracked by GlobalData were:

• Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings and T Rowe Price Associates’ $200 million venture financing of Tempus Labs.
• The $150 million venture financing of Singlera Genomics by CICC Kai Tak Fund, DETONG Capital Partners, FutureX Skyline Capital, Huamei International, Linden Asset Management, Prosperico Ventures, Proxima Ventures, Shanghai Free Trade Zone Fund Tao Capital, Shanghai Furong Investment, Shenzhen Green Pine Capital Partners and Wuxi Financial Investment.
• CCB International Capital, China International Capital, China Renaissance Holdings, China Structural Reform Fund, CICC Capital ManagementLimited, GL Ventures, Matrix Partners China and Taikang Asset Management’s $149 million venture financing of GeneCast Biotechnology.
• The $120 million venture financing of Cytek Biosciences by Hillhouse Capital Group, LYFE Capital, Orbimed Advisors and RA Capital Management.
• ACE &SA, Alychlo, aMoon Partners, Credit Suisse Group, Endeavour Vision, Eurazeo Growth, Famille C Invest, Generation Investment Management, Hitachi Ventures, Pictet & Cie Group and Swisscom Ventures’ venture financing of Sophia Genetics for $110 million.